IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is based in Richland, Washington.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:ISR
CUSIPN/A
Phone+1-509-3751202
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-95.25%
Return on Equity-69.11%
Return on Assets-58.22%
Miscellaneous
EmployeesN/A
Outstanding Shares56,330,000
Market Cap$24.87 million
IsoRay (NYSEAMERICAN:ISR) Frequently Asked Questions
What is IsoRay's stock symbol?
IsoRay trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."
How were IsoRay's earnings last quarter?
IsoRay, Inc. (NYSEAMERICAN:ISR) posted its earnings results on Thursday, May, 3rd. The healthcare company reported ($0.02) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.03) by $0.01. The healthcare company earned $1.57 million during the quarter. IsoRay had a negative return on equity of 69.11% and a negative net margin of 95.25%. View IsoRay's Earnings History.
When is IsoRay's next earnings date?
What price target have analysts set for ISR?
2 Wall Street analysts have issued 12 month price targets for IsoRay's shares. Their predictions range from $1.00 to $2.00. On average, they anticipate IsoRay's share price to reach $1.50 in the next year. This suggests a possible upside of 163.2% from the stock's current price. View Analyst Price Targets for IsoRay.
What is the consensus analysts' recommendation for IsoRay?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoRay in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IsoRay.
Are investors shorting IsoRay?
IsoRay saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 791,915 shares, an increase of 28.6% from the July 13th total of 615,808 shares. Based on an average daily volume of 1,894,934 shares, the days-to-cover ratio is currently 0.4 days. Currently, 1.2% of the shares of the company are sold short. View IsoRay's Current Options Chain.
Who are some of IsoRay's key competitors?
Some companies that are related to IsoRay include Bovie Medical (BVX), InfuSystem (INFU), Retractable Technologies (RVP), Milestone Scientific (MLSS), Akers Biosciences (AKR), Daxor (DXR), Omega Diagnostics Group (ODX), Relevium Technologies (RLV), Vigil Health Solutions (VGL), Iris Biotechnologies (IRSB), SECTOR 10 (SECI), Lifestyle Delivery Systems (LDSYF) and RESMED/IDR UNRESTR (RMD).
Who are IsoRay's key executives?
IsoRay's management team includes the folowing people:
- Mr. William Cavanagh III, COO & Chief Scientific Officer (Age 52)
- Mr. Michael L. Krachon, VP of Sales & Marketing (Age 47)
- Ms. Lori A. Holmes-Woods, Interim Chief Exec. Officer (Age 56)
- Mr. Mark Austin CPA, Principal Accounting & Financial Officer and Controller (Age 31)
- Mrs. Jennifer Streeter, VP of HR (Age 48)
Has IsoRay been receiving favorable news coverage?
News articles about ISR stock have trended somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. IsoRay earned a coverage optimism score of 0.22 on Accern's scale. They also assigned press coverage about the healthcare company an impact score of 48.33 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for IsoRay.
How do I buy shares of IsoRay?
Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IsoRay's stock price today?
One share of ISR stock can currently be purchased for approximately $0.57.
How big of a company is IsoRay?
IsoRay has a market capitalization of $24.87 million.
How can I contact IsoRay?
IsoRay's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at +1-509-3751202.
MarketBeat Community Rating for IsoRay (NYSEAMERICAN ISR)
MarketBeat's community ratings are surveys of what our community members think about IsoRay and other stocks. Vote "Outperform" if you believe ISR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISR will underperform the S&P 500 over the long term. You may vote once every thirty days.
